Exploration of Fluorinated Pyrazolidine‐3,5‐Diones for Positron Emission Tomography Imaging of the P2Y <sub>12</sub> Receptor in the Central Nervous System

The purinergic receptor P2Y<sub>12</sub> (P2Y<sub>12</sub>R) has emerged as a promising biomarker for selectively imaging the anti-inflammatory phenotype of microglia. Developing positron emission tomography (PET) tracers for this target is an active area of research, as imaging of specific microglial phenotypes can provide valuable insights into their dynamics in neuroinflammation. A key challenge is identifying high affinity P2Y<sub>12</sub>R ligands with optimal properties for targeting this receptor in the central nervous system (CNS). Herein, the synthesis and evaluation of a series of fluorinated pyrazolidine-3,5-dione derivatives are conducted as potential P2Y<sub>12</sub>R PET tracers, designed based on a literature compound with promising physicochemical properties for brain permeability. All synthesized derivatives exhibit strong affinity for the human P2Y<sub>12</sub>R in vitro, with K<sub>i</sub> values ranging from 1.21 to 5.66 nM. One candidate is selected for radiolabeling with fluorine-18 ([<sup>18</sup>F]8) and evaluated in healthy rats using dynamic PET imaging, as well as ex vivo biodistribution and metabolism studies. Unfortunately, [<sup>18</sup>F]8 shows low brain uptake, potentially due to deprotonation of the pyrazolidine-3,5-dione scaffold in vivo, in addition to a rapid metabolism. These findings highlight the need for novel chemical entities as starting points for tracer development to target the P2Y<sub>12</sub>R in the CNS.

Authors

Institutions

Publication Details

Journal
ChemMedChem
Published
2025-08-11
DOI
https://doi.org/10.1002/cmdc.202500483
Citations
1
Primary Topic
Neuroscience and Neuropharmacology Research
Type
article
Field-Weighted Citation Impact
0.91

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exploration of Fluorinated Pyrazolidine‐3,5‐Diones for Positron Emission Tomography Imaging of the P2Y 12 Receptor in the Central Nervous System

Robert C. Schuit, Albert D. Windhorst, E. Johanna L. Stéen, Barbara Zarzycka et al.
1 citations
ChemMedChem
Neuroscience and Neuropharmacology Research
0.91
article

Exploration of Fluorinated Pyrazolidine‐3,5‐Diones for Positron Emission Tomography Imaging of the P2Y 12 Receptor in the Central Nervous System

Robert C. Schuit, Albert D. Windhorst, E. Johanna L. Stéen, Barbara Zarzycka, Iwan J. P. de Esch, Berend van der Wildt, Wissam Beaino, Pedro Pereira, Mariska Verlaan, A. Olivier, Khaled Alkayal, Leopoldo J. Gabella Carena
article en
1 citations

Abstract

The purinergic receptor P2Y<sub>12</sub> (P2Y<sub>12</sub>R) has emerged as a promising biomarker for selectively imaging the anti-inflammatory phenotype of microglia. Developing positron emission tomography (PET) tracers for this target is an active area of research, as imaging of specific microglial phenotypes can provide valuable insights into their dynamics in neuroinflammation. A key challenge is identifying high affinity P2Y<sub>12</sub>R ligands with optimal properties for targeting this receptor in the central nervous system (CNS). Herein, the synthesis and evaluation of a series of fluorinated pyrazolidine-3,5-dione derivatives are conducted as potential P2Y<sub>12</sub>R PET tracers, designed based on a literature compound with promising physicochemical properties for brain permeability. All synthesized derivatives exhibit strong affinity for the human P2Y<sub>12</sub>R in vitro, with K<sub>i</sub> values ranging from 1.21 to 5.66 nM. One candidate is selected for radiolabeling with fluorine-18 ([<sup>18</sup>F]8) and evaluated in healthy rats using dynamic PET imaging, as well as ex vivo biodistribution and metabolism studies. Unfortunately, [<sup>18</sup>F]8 shows low brain uptake, potentially due to deprotonation of the pyrazolidine-3,5-dione scaffold in vivo, in addition to a rapid metabolism. These findings highlight the need for novel chemical entities as starting points for tracer development to target the P2Y<sub>12</sub>R in the CNS.

ChemMedChemVol. 20(17)
Amsterdam Neuroscience (NL), Vrije Universiteit Amsterdam (NL)
Michael J. Fox Foundation for Parkinson's Research, European Commission, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, H2020 Marie Skłodowska-Curie Actions
Good health and well-being
Openalex Percentile: Top 24%
Neuroscience and Neuropharmacology Research
0.91
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.